Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

HIV’s Tat protein blocks autophagy in macrophages, letting Mtb thrive. This may explain why HIV patients face higher TB risk even on ART.

The initiative is part of a broader campaign to ensure a healthy and stigma-free working environment within the justice ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which is viewed as a key part of the drugmaker's growth strategy in HIV. The ...

Cheap generic versions of a groundbreaking HIV-prevention jab should be available in more than 100 countries from 2027, ...

Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...

Calls to replenish the Global Fund have been renewed as the worldwide battle against Aids, tuberculosis and malaria is ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

A clear look at how HIV impacts health and why early testing can make a difference. Major Bay Area sideshow crackdown: 22 cars seized, felony arrests made in sweep Ryder Cup emcee apologizes to Rory ...

New study findings could change treatments for HIV in young children. HIV remission may be possible for very young children ...

Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 a year in more than 100 ...

Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...